Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]FAPI PET/CT in non-resolving ARDS
2024-517257-27-00Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 68Ga FAPI-46 in acute respiratory distress syndrome (ARDS), sponsored by University Medical Center Groningen. Primary endpoints: [68Ga]FAPI uptake related to 28-day mortality, [68Ga]FAPI uptake related to ICU stay and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
68Ga FAPI-46
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-517257-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517257-27-00.